Make Better Decisions

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Baxter
Novartis
Medtronic
Argus Health
QuintilesIMS
UBS
Boehringer Ingelheim
Farmers Insurance
US Army

Generated: January 16, 2018

DrugPatentWatch Database Preview

EMEND Drug Profile

« Back to Dashboard

When do Emend patents expire, and when can generic versions of Emend launch?

Emend is a drug marketed by Merck, Msd Merck Co, and Merck And Co Inc. and is included in three NDAs. There are three patents protecting this drug and four Paragraph IV challenges.

This drug has one hundred and twenty-four patent family members in forty-eight countries and seven supplementary protection certificates in four countries.

The generic ingredient in EMEND is fosaprepitant dimeglumine. There are nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.

US Patents and Regulatory Information for EMEND

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 AP RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 AB RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 AB RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 DISCN Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Msd Merck Co EMEND aprepitant FOR SUSPENSION;ORAL 207865-001 Dec 17, 2015 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for EMEND

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-001 Jan 25, 2008 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Subscribe ➤ Subscribe
Merck And Co Inc EMEND fosaprepitant dimeglumine POWDER;INTRAVENOUS 022023-002 Nov 12, 2010 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for EMEND
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe for Oral Suspension 125 mg/Kit ➤ Subscribe 11/23/2016
➤ Subscribe Injection 115 mg/vial ➤ Subscribe 1/25/2012
➤ Subscribe Injection 150 mg/vial ➤ Subscribe 1/25/2012
➤ Subscribe Capsule 40 mg, 80 mg and 125 mg ➤ Subscribe 11/3/2008

Non-Orange Book US Patents for EMEND

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,432,953 Polymorphic form of a tachykinin receptor antagonist ➤ Subscribe
5,512,570 Treatment of emesis with morpholine tachykinin receptor antagonists ➤ Subscribe
5,716,942 Treatment of migraine with morpholine tachykinin receptor antagonists ➤ Subscribe
6,583,142 Polymorphic form of a tachykinin receptor antagonist ➤ Subscribe
6,229,010 Polymorphic form of a tachykinin receptor antagonist ➤ Subscribe
5,780,467 Morpholine compounds are prodrugs useful as tachykinin receptor antagonists ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for EMEND

Supplementary Protection Certificates for EMEND

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0010 France ➤ Subscribe PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
2004002,C0734381 Lithuania ➤ Subscribe PRODUCT NAME: 5-(((2R,3S)-2-((1R)-1-(3,5-BIS(TRIFLUORMETIL)FENIL)ETOKSI)-3-(4-FLUORFENIL)-4-MORFOLINIL)METIL)-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO/DATE: EU/1/03/262/001, 2003 11 11, EU/1/03/262/002, 2003 11 11, EU/1/03/262/003, 2003 11 11, EU/1/03/262/004, 2003 11 11, EU/1/03/262/005, 2003 11 11, EU/1/03/262/006 20031111
C0019 France ➤ Subscribe PRODUCT NAME: FOSAPREPITANT DIMEGLUMINE; REGISTRATION NO/DATE: EU/1/07/437/001 20080111
C/GB04/011 United Kingdom ➤ Subscribe PRODUCT NAME: APREPITANT, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/03/262/001 20031113; UK EU/1/03/262/002 20031113; UK EU/1/03/262/003 20031113; UK EU/1/03/262/004 20031113; UK EU/1/03/262/005 20031113; UK EU/1/03/262/006 20031113
C/GB08/021 United Kingdom ➤ Subscribe PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
2004 Austria ➤ Subscribe PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
2004002 Lithuania ➤ Subscribe PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Deloitte
Johnson and Johnson
Argus Health
Baxter
US Department of Justice
Federal Trade Commission
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot